BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32519226)

  • 21. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.
    Zhang JX; Ji MY; Song J; Lei HB; Qiu S; Wang J; Ai MH; Wang J; Lv XG; Yang ZR; Dong WG
    World J Gastroenterol; 2013 Dec; 19(45):8408-19. PubMed ID: 24363534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
    Kahrilas PJ; Howden CW; Hughes N
    Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical treatments of GERD: the old and new.
    Vela MF
    Gastroenterol Clin North Am; 2014 Mar; 43(1):121-33. PubMed ID: 24503363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
    Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G
    Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.
    Richter JE; Kumar A; Lipka S; Miladinovic B; Velanovich V
    Gastroenterology; 2018 Apr; 154(5):1298-1308.e7. PubMed ID: 29305934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
    Hillman L; Yadlapati R; Thuluvath AJ; Berendsen MA; Pandolfino JE
    Dis Esophagus; 2017 Sep; 30(9):1-15. PubMed ID: 28859358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.
    Kung YM; Hsu WH; Wu MC; Wang JW; Liu CJ; Su YC; Kuo CH; Kuo FC; Wu DC; Wang YK
    Dig Dis Sci; 2017 Dec; 62(12):3298-3316. PubMed ID: 29110162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.
    Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
    Dis Esophagus; 2017 May; 30(5):1-9. PubMed ID: 28375448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal reflux disease: prospective study.
    Ezzat WF; Fawaz SA; Fathey H; El Demerdash A
    J Otolaryngol Head Neck Surg; 2011 Aug; 40(4):350-6. PubMed ID: 21777555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.
    Hershcovici T; Fass R
    Drugs; 2011 Dec; 71(18):2381-9. PubMed ID: 22117130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.
    Cohen S; Bueno de Mesquita M; Mimouni FB
    Br J Clin Pharmacol; 2015 Aug; 80(2):200-8. PubMed ID: 25752807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of severe symptomatic gastroesophageal reflux disease.
    Talley NJ; Zand Irani M
    J Intern Med; 2021 Feb; 289(2):162-178. PubMed ID: 32691466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nissen fundoplication
    Zhang C; Hu ZW; Yan C; Wu Q; Wu JM; Du X; Liu DG; Luo T; Li F; Wang ZG
    World J Gastroenterol; 2017 May; 23(19):3546-3555. PubMed ID: 28596691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination drug therapy for gastroesophageal reflux disease.
    Cross LB; Justice LN
    Ann Pharmacother; 2002 May; 36(5):912-6. PubMed ID: 11978171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.